ORIC Pharmaceuticals

Historical price data

ORIC Pharmaceuticals is a clinical-stage biotech with a mission to overcome therapeutic resistance in cancer, a primary cause of treatment failure. The company has successfully raised over $900 million, advanced four programs into clinical trials, and is progressing key assets like ORIC-114 and rinzimetostat (ORIC-944) in late-phase 1b/2 studies. Its strategy centers on a proprietary resistance platform to develop combination therapies that extend the efficacy of standard-of-care treatments, positioning it as a potential partner of choice in the oncology landscape.

A systematic resistance platform focused on identifying and targeting three categories of cancer treatment failure: innate, acquired, and bypass resistance, utilizing translational models to develop combination therapies.

ORIC competes with both large pharma and biotechs developing next-generation monotherapies and combination strategies. Its primary differentiation is a platform and pipeline wholly dedicated to overcoming defined resistance mechanisms, aiming for best-in-class profiles in specific combination settings.